NewGen’s total shares outstanding count expected to reach 5.9 million following recently announced share issuance, bolstering market capitalization
NewGen’s agreed 13% stake in K25.ai is now valued at approximately
NewGen reported net profit attributable to shareholders of
Based on a current implied valuation of
Upon completion of the issuance of 2,500,000 Class A ordinary shares as announced on
About NewGen
NewGenIVF Group Limited is a technology-forward, diversified growth company pursuing opportunities across real estate development, digital asset innovation, and reproductive health solutions. The Company operates through NewGenProperty, focused on real estate development projects in Ras Al Khaimah, United Arab Emirates; NewGenDigital, focused on digital asset and decentralized-finance solutions; and NewGenSup, focused on health and longevity products and solutions. NewGenIVF’s legacy business includes IVF and assisted reproductive treatment services across Asia. To learn more, visit www.nivf.global. Information contained on, or accessible through, the Company’s website is not incorporated by reference into this press release.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding: the expected completion of NewGen's acquisitions of equity interests in K25.ai and the resulting aggregate ownership of 13%; the implied valuation of K25.ai and the corresponding value of NewGen's stake and expected unrealized gain; the anticipated completion of the previously announced issuance of Class A ordinary shares and its expected effect on total shares outstanding and market capitalization; and characterizations of the Company's financial position, balance sheet strength, and growth trajectory in connection with the K25.ai investment.
These forward-looking statements are based on the Company's current expectations, estimates, projections and assumptions as of the date of this press release and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied. These risks and uncertainties include, among others: the risk that the acquisitions of equity stakes in K25.ai are not completed on the terms described or at all; the risk that the carrying value of the Company's investment in K25.ai is not realized and may be impaired; and share dilution and capital markets issuance risk. Additional risks are described in the Company's Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission.
All information provided in this press release is as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable securities laws.
Contacts
ICR, LLC
Robin Yang
Phone: +1 (212) 537-3847
Email: Newgenivf.IR@icrinc.com
Source: NewGenIVF Group Limited